Published in J Invasive Cardiol on March 01, 2006
The influence of CYP 2C19*2 polymorphism on platelet function testing during single antiplatelet treatment with clopidogrel. Thromb J (2011) 0.81
Assessment of Myocardial Ischemia in Obese Individuals Undergoing Physical Stress Echocardiography (PSE). Arq Bras Cardiol (2015) 0.80
Validity of a PCI Bleeding Risk Score in patient subsets stratified for body mass index. Open Heart (2015) 0.78
Impaired T(H)17 cell differentiation in subjects with autosomal dominant hyper-IgE syndrome. Nature (2008) 8.17
Use of antioxidant vitamins for the prevention of cardiovascular disease: meta-analysis of randomised trials. Lancet (2003) 5.34
Convergence of atherosclerosis and Alzheimer's disease: inflammation, cholesterol, and misfolded proteins. Lancet (2004) 3.51
Meta-analysis of Dense Genecentric Association Studies Reveals Common and Uncommon Variants Associated with Height. Am J Hum Genet (2010) 2.15
Intravascular ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. J Am Coll Cardiol (2010) 2.05
Hospital characteristics associated with feeding tube placement in nursing home residents with advanced cognitive impairment. JAMA (2010) 1.91
Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS). Clin Transl Sci (2012) 1.76
Impact of blood transfusion on short- and long-term mortality in patients with ST-segment elevation myocardial infarction. JACC Cardiovasc Interv (2009) 1.64
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. Clin Chem (2009) 1.51
Efficacy of a novel procedure sheath and closure device during diagnostic catheterization: the multicenter randomized clinical trial of the FISH device. J Invasive Cardiol (2008) 1.44
Highly variable clinical phenotypes of hypomorphic RAG1 mutations. Pediatrics (2010) 1.30
A role for semaphorin 3A signaling in the degeneration of hippocampal neurons during Alzheimer's disease. J Neurochem (2004) 1.04
Long-term cost effectiveness of early and sustained dual oral antiplatelet therapy with clopidogrel given for up to one year after percutaneous coronary intervention results: from the Clopidogrel for the Reduction of Events During Observation (CREDO) trial. J Am Coll Cardiol (2005) 1.01
Risk factors for premature coronary artery disease and determinants of adverse outcomes after revascularization in patients < or =40 years old. Am J Cardiol (2003) 0.98
Impact of female sex on death and bleeding after fibrinolytic treatment of myocardial infarction in GUSTO V. Arch Intern Med (2007) 0.98
Novel micro-bioreactor high throughput technology for cell culture process development: Reproducibility and scalability assessment of fed-batch CHO cultures. Biotechnol Bioeng (2010) 0.92
Rapid protein production using CHO stable transfection pools. Biotechnol Prog (2010) 0.90
Comprehensive peroxidase-based hematologic profiling for the prediction of 1-year myocardial infarction and death. Circulation (2010) 0.90
Direct-to-consumer genetic testing: reliable or risky? Clin Chem (2011) 0.89
Optimization of a glycoengineered Pichia pastoris cultivation process for commercial antibody production. Biotechnol Prog (2011) 0.88
Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates < or = 60 versus > 60 ml/min/1.73 m(2): a meta-analysis of intravascular ultrasound studies. Am J Cardiol (2007) 0.87
Integrative medicine: implementation and evaluation of a professional development program using experiential learning and conceptual change teaching approaches. Patient Educ Couns (2006) 0.87
Coronary abnormalities in hyper-IgE recurrent infection syndrome: depiction at coronary MDCT angiography. AJR Am J Roentgenol (2009) 0.85
Incidence, predictors, and outcomes of high-degree atrioventricular block complicating acute myocardial infarction treated with thrombolytic therapy. Am Heart J (2005) 0.84
Association between inflammatory biomarkers and platelet aggregation in patients under chronic clopidogrel treatment. Thromb Haemost (2010) 0.83
Improving cardiovascular outcomes using electronic health records. Curr Cardiol Rep (2014) 0.83
Relationship between baseline inflammatory markers, antiplatelet therapy, and adverse cardiac events after percutaneous coronary intervention: an analysis from the clopidogrel for the reduction of events during observation trial. Circ Cardiovasc Interv (2009) 0.82
Clinical implications of percutaneous coronary intervention-clopidogrel in unstable angina to prevent recurrent events (PCI-CURE) study: a US perspective. Circulation (2002) 0.81
Risk for cardiovascular outcomes among subjects with atherosclerotic cardiovascular disease and greater-than-normal estimated glomerular filtration rate. Clin J Am Soc Nephrol (2007) 0.80
Annals Q&A with Dr. Eric Topol. Interview by Truman J Milling Jr. Ann Emerg Med (2012) 0.80
Plaque progression in coronary arteries with minimal luminal obstruction in intravascular ultrasound atherosclerosis trials. Am J Cardiol (2010) 0.79
Progression of coronary atherosclerosis in African-American patients. Cardiovasc Diagn Ther (2013) 0.79
Intravenous nicardipine and labetalol use in hypertensive patients with signs or symptoms suggestive of end-organ damage in the emergency department: a subgroup analysis of the CLUE trial. BMJ Open (2013) 0.79
Bone density and fractures in autosomal dominant hyper IgE syndrome. J Clin Immunol (2014) 0.78
Long-term outcomes and clinical predictors for pacemaker-requiring bradyarrhythmias after cardiac transplantation: analysis of the UNOS/OPTN cardiac transplant database. Heart Rhythm (2010) 0.78
The impact of changing antiseptic skin preparation agent used for cardiac implantable electronic device (CIED) procedures on the risk of infection. Pacing Clin Electrophysiol (2014) 0.77
The management of acute hypertension in patients with renal dysfunction: labetalol or nicardipine? Postgrad Med (2014) 0.77
Timing and correlates of very early major adverse clinical events following percutaneous coronary intervention. J Invasive Cardiol (2008) 0.77
Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention. Am Heart J (2010) 0.77
A call to action: lowering the cost of health care. Am J Prev Med (2013) 0.77
Assessing aspirin responsiveness in subjects with multiple risk factors for vascular disease with a rapid platelet function analyzer. Blood Coagul Fibrinolysis (2004) 0.77
Peroxisome proliferator-activated receptor gamma agonists for the Prevention of Adverse events following percutaneous coronary Revascularization--results of the PPAR study. Am Heart J (2007) 0.77
Inventing the future. Health Data Manag (2014) 0.76
RNase P ribozymes for the studies and treatment of human cytomegalovirus infections. J Clin Virol (2002) 0.76
Impact of chronic antiplatelet therapy before hospitalization on ischemic and bleeding events in invasively managed patients with acute coronary syndromes: the ACUITY trial. Eur J Cardiovasc Prev Rehabil (2011) 0.76
Engineered RNase P ribozymes inhibit gene expression and growth of cytomegalovirus by increasing rate of cleavage and substrate binding. J Mol Biol (2002) 0.76
Author response to comment on "characterization of circulating endothelial cells in acute myocardial infarction". Sci Transl Med (2012) 0.75
Dynamic J-Point Elevation Associated with Epileptic Hemiplegia: The Osborn Wave of Todd's Paralysis. Case Rep Neurol (2013) 0.75
Aspirin resistance and its implications in clinical practice. MedGenMed (2005) 0.75
Effectiveness of 6 months of tailored text message reminders for obese male participants in a worksite weight loss program: randomized controlled trial. JMIR Mhealth Uhealth (2015) 0.75
Optimal treatment and current situation in reperfusion after thrombolysis for acute myocardial infarction. Ann Med (2002) 0.75
Exciting interventions in individualized medicine. An interview with Eric Topol, MD, of the Scripps Translational Science Institute by Elaine Musgrave, PhD. Clin Transl Sci (2009) 0.75
What he should say. Healthcare leaders offer suggestions for state of the union. Mod Healthc (2013) 0.75
Embracing the future. We need another Flexner report to shake up and restructure healthcare. Mod Healthc (2012) 0.75
Here and now--state of the art: optimal antithrombotic strategy for percutaneous coronary intervention-panel discussion. J Invasive Cardiol (2004) 0.75
A discussion with digital health pioneer Dr. Eric Topol. Interview by Paul Webster. CMAJ (2013) 0.75
Population attributable fraction: its implications for genetic epidemiology and illness prevention. Am Heart J (2007) 0.75